Any feedback?
Literature summary for 3.4.24.69 extracted from
- Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin (2010), Pain, 149, 316-324.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | BoNT-A can be administered subcutaneously or topically, in addition to the common application by intradermal and intramuscular injection, with a transdermal delivery peptide to reduce inflammation produced by activating nociceptors in the skin. Peptide-mediated delivery of BoNT-A is an easy and non-invasive way of administering the toxin that may prove to be useful in clinical practice, overview | Clostridium botulinum |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Clostridium botulinum | - |
- |
- |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|---|---|---|
| commercial preparation | - |
Clostridium botulinum | - |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| BoNT-A | - |
Clostridium botulinum |
| botulinum neurotoxin type A | - |
Clostridium botulinum |
General Information
| General Information | Comment | Organism |
|---|---|---|
| additional information | the short synthetic peptide TD-1 can facilitate effective transdermal delivery of BoNT-A through intact skin. Coadministration of TD-1 and BoNT-A to the hindpaw skin of Sprague-Dawley rats results in a significant reduction in plasma extravasation evoked by electrical stimulation, also but less in plasma extravasation evoked by capsaicin. Subcutaneous administration of BoNT-A also reduces vasodilation caused by saphenous nerve stimulation. BoNT-A does not interfere with substance P- and calcitonin gene-related peptide-induced vasodilation | Clostridium botulinum |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
